Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Why the Imugene (ASX:IMU) share price has soared over 300% this year

The share price of biotechnology company Imugene Limited (ASX: IMU) has been on a tear this year. Here's why the Imugene share price is flying.

The share price of biotechnology company Imugene Limited (ASX: IMU) has been on a tear this year.

Imugene shares are up another 13% today at the time of writing, meaning the share price has soared over 300% in the year to date.

With a market capitalisation now exceeding $600 million, Imugene is beginning to appear on the radar of many investors.

Imugene became listed on the ASX in December 2013 via a reverse takeover of Biolife Science.

What does Imugene do?

Imugene is a biotechnology company that develops a range of cancer immunotherapy treatments. According to the Cancer Council Australia, “immunotherapy aims to boost the body’s own immune system to fight cancer”.

More specifically, Imugene has a pipeline of B-cell immunotherapy vaccines in development, including HER-Vaxx, which targets tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has received the most attention of late – more on this later.

Imugene is also working towards developing other vaccines such as PD1-Vaxx, which blocks PD1-signalling (a protein that exerts a negative effect on immune responses). Imugene believes PD1-Vaxx could play a role in treating tumours such as non-small cell lung cancer.

Additionally, in July last year, Imugene acquired the exclusive rights to CCF33 oncolytic virus technologies. Oncolytic viruses are those that can infect and destroy cancer cells.

Imugene’s recent big announcement

Yesterday, Imugene announced very positive results from its HER-Vaxx Ongoing Randomized Phase 2 advanced gastric cancer trial.

Interim analysis revealed that the median overall survival for patients receiving HER-Vaxx vaccine in addition to chemotherapy was 14.2 months. This compares favourably to the 8.8-month median overall survival for patients treated with just chemotherapy.

Amongst other findings, the group receiving HER-Vaxx resulted in a reduced risk of death of 58.2% when compared to the group receiving only chemotherapy, giving a hazard ratio of 0.418.

Pleasingly, the Independent Data Monitoring Committee verified positive survival outcomes and confirmed HER-Vaxx in combination with chemotherapy did not result in added toxicity.

Is the Imugene share price a buy?

Imugene’s pipeline and recent announcement have clearly generated a lot of buzz. As at the quarter ended 30 September, Imugene is not yet generating revenue. For the quarter, Imugene spent $4.2 million on research on development and used a net total of $4.9 million of cash on operating activities.

Perhaps I am too conservative, but I would like to see Imugene start earning revenue before getting excited. At that point, the Imugene share price could be multiples higher from where it is today. Conversely, it could be far lower if revenues do not materialise as hoped. Mesoblast Limited (ASX: MSB) is a great example of the wild share price volatility that can transpire for biotechs.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, the author of this article does not have a financial or commercial interest in any of the companies mentioned
Skip to content